From Financial Modeling Prep: 2025-05-06 02:15:00

President Trump signed an executive order to reshore pharmaceutical production and reduce U.S. reliance on imported drugs, potentially impacting major global pharma exporters. FDA will expedite domestic plant approvals, EPA will fast-track permits for U.S. facilities, and tariffs on imported drugs may be implemented within two weeks.

Trump deems foreign drug imports a national security risk, with over $200 billion in annual U.S. pharma imports. Key countries at risk include India, China, and EU states, as their pharmaceutical giants heavily rely on U.S. demand. Major players like Roche and Novartis are already increasing U.S. production to mitigate potential tariffs.

The move could reshape the global pharma landscape, with increased investment in U.S. manufacturing and strained international supply chains. Companies in the pharmaceutical and medical device sectors can use tools like Individual Industry Classification and Revenue Product Segmentation APIs to assess exposure to U.S. sales and product-level revenue breakdowns.



Read more at Financial Modeling Prep:: Trump Targets Pharma Imports with Executive Order …